The evolution of prostacyclins in pulmonary arterial hypertension: from classical treatment to modern management (original) (raw)

Prostacyclin Use Among Patients with Pulmonary Arterial Hypertension in the United States: A Retrospective Analysis of a Large Health Care Claims Database

Charles D Burger

Journal of managed care & specialty pharmacy, 2017

View PDFchevron_right

Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension : Another Step Forward

Aaron Waxman

View PDFchevron_right

Transition from Prostacyclin Analogue Infusion to Oral Therapy in Patients with Pulmonary Arterial Hypertension: A Five Year Follow-Up

Tahir Jameel

Journal of the American College of Cardiology, 2013

View PDFchevron_right

Transition from prostacyclin analogue infusion to oral therapy in patients with pulmonary arterial hypertension: a 5-year follow-up

Tahir Ahmed

Pulmonary circulation, 2013

View PDFchevron_right

Role of prostacyclin in pulmonary hypertension

Nura Mohamed

Global Cardiology Science and Practice, 2014

View PDFchevron_right

Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis

Mohammad Eddama

Journal of Clinical Medicine

View PDFchevron_right

Diverse Pharmacology of Prostacyclin Mimetics: Implications for Pulmonary Hypertension

Lucie Clapp

Molecular Mechanism of Congenital Heart Disease and Pulmonary Hypertension, 2020

View PDFchevron_right

Prostacyclin Administration Errors in Pulmonary Arterial Hypertension Patients Admitted to Hospitals in the United States: A National Survey

Martha Kingman

CHEST Journal, 2009

View PDFchevron_right

Practical considerations for therapies targeting the prostacyclin pathway

Wendy Gin-Sing

European Respiratory Review, 2016

View PDFchevron_right

Prostacyclin and its analogues in the treatment of pulmonary hypertension

Andrea Olschewski, Werner Seeger

Pharmacology & Therapeutics, 2004

View PDFchevron_right

Saudi experience in the management of pulmonary arterial hypertension; The outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin

Enas Batubara

Annals of Thoracic Medicine

View PDFchevron_right

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol)

W. Tomkowski

Annals of Internal …, 1990

View PDFchevron_right

Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost

George Cremona

Heart (British Cardiac Society), 1998

View PDFchevron_right

Cost Effectiveness of Prostacyclins in Pulmonary Arterial Hypertension

Antonio Román

Applied Health Economics and Health Policy, 2012

View PDFchevron_right

Prostacyclin and Iloprost in the Treatment of Primary Pulmonary Hypertension

Christopher McCabe

View PDFchevron_right

Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue

Sergio Morelli

Heart (British Cardiac Society), 2001

View PDFchevron_right

Current Pharmacological Treatment of Pulmonary Arterial Hypertension

Paschalis Steiropoulos

Current Clinical Pharmacology, 2008

View PDFchevron_right

Management Of Pulmonary Arterial Hypertension: A Brief Overview

Shatavisa Mukherjee

2017

View PDFchevron_right

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost

Roxana Sulica

Pulmonary Circulation, 2013

View PDFchevron_right

Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects

Rafal Nizankowski

Circulation, 1999

View PDFchevron_right

Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

Marcin Kurzyna

European Respiratory Journal, 2012

View PDFchevron_right

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

Meinhard Kneussl

Journal of the American College of Cardiology, 2002

View PDFchevron_right

Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing

Michela Boromei

Journal of Clinical Medicine

View PDFchevron_right

Transition From Prostacyclin to Bosentan in Five Patients With Severe Pulmonary Hypertension: the Switch Is Possible

Miguel Sanchez

Revista Espanola De Cardiologia, 2006

View PDFchevron_right

Efficiency of Prostacyclin in the Treatment of Protamine-Mediated Right Ventricular Failure and Acute Pulmonary Hypertension

Ilker Kiris

The Tohoku Journal of Experimental Medicine, 2005

View PDFchevron_right

Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension

Dermot O'Callaghan

Respiratory Medicine, 2010

View PDFchevron_right

Conversion to Bosentan From Prostacyclin Infusion Therapy in Pulmonary Arterial Hypertension *

H. Farber

CHEST Journal, 2006

View PDFchevron_right

Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease

Decho Jakrapanichakul

Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005

View PDFchevron_right

Clinical and cost effectiveness of treatments for pulmonary arterial hypertension (PAH) within their licensed indications

Sue Jowett

View PDFchevron_right

New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension

Ryozo Nagai

Cardiovascular Drugs and Therapy, 2006

View PDFchevron_right

A review of pulmonary arterial hypertension: Part 2: Current and expected treatments

Pieter E Postmus

View PDFchevron_right

Key Articles and Guidelines in the Management of Pulmonary Arterial Hypertension: 2011 Update

Tyree Kiser

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012

View PDFchevron_right